Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Zhang Y is active.

Publication


Featured researches published by Zhang Y.


Chinese Journal of Hematology | 2014

A study of prognostic value of cytogenetics in patients with primary myelofibrosis

Li B; Junqing Xu; Xu Zf; Chengwen Li; Qin Tj; Fang Lw; Zhang Hl; Hu N; Pan Lj; Qu S; Wang J; Zhang Y; Peihong Zhang; Xiao Zj

OBJECTIVEnTo evaluate the prognostic value of cytogenetics in Chinese with primary myelofibrosis (PMF).nnnMETHODSnFour hundred and thirty-nine Chinese patients with PMF were retrospectively analyzed. The Kaplan-Meier method, the Log-rank test, the likelihood ratio test and the COX proportional hazards regression model were used to evaluate the prognostic scoring systems.nnnRESULTSnFour hundred and thirty-nine Chinese patients with PMF were analyzed with a median age of 56 years (range: 8-83), including 298 males and 141 females. The DIPSS-plus system could effectively evaluate prognosis in Chinese patients with PMF. There was significantly higher predictive power for survival for the DIPSS-plus group compared with the DIPSS group (P=0.006, -2 log-likelihood ratios of 989.5 and 1001.9 for the DIPSS-plus and DIPSS systems, respectively). Univariate analysis indicated that the patients with a normal karyotype, a complex karyotype that was not a monosomal karyotype, +8 only or a balanced translocation only had better survival. Following two cytogenetic risk categories were constructed: favorable karyotype including subjects with a normal karyotype, a complex karyotype that was not a monosomal karyotype, +8 only or a balanced translocation only and unfavorable karyotype included all others. The modified DIPSS-Chinese prognostic model was proposed by adopting cytogenetic categories and DIPSS- Chinese risk group. The median survival of patients classified in low risk (163 subjects), intermediate-1 risk (187 subjects), intermediate-2 risk (82 subjects) and high risk (7 subjects) were not reached, 74 (95% CI 42-106), 39 (95% CI 26-52) and 12(95% CI 1-25)months, respectively, and there was a statistically significant difference in overall survival among the four risk groups (P<0.01).nnnCONCLUSIONnThe DIPSS-plus had significantly higher predictive power than the DIPSS group in Chinese patients with PMF and the modified DIPSS-Chinese system based on the cytogenetic features of Chinese patients was proposed and worked well for prognostic indication.


Chinese Journal of Hematology | 2010

Study on NPM1 gene mutations in patients with primary myelodysplastic syndromes

Li L; Zhang Y; Ma Xt; Yang L; Xu Zf; Xiao Zj


Chinese Journal of Hematology | 2010

Cyclosporine A in combination with thalidomide for the treatment of patients with myelodysplastic syndromes

Xu Zf; Qin Tj; Zhang Y; Liu Kq; Hao Ys; Xiao Zj


Chinese Journal of Hematology | 2009

[The prognostic value of a modified WPSS based on routine laboratory parameters in patients with myelodysplastic syndromes: a preliminary result].

Li L; Nie L; Yu Mh; Yu Y; Liu L; Qin Tj; Xu Zf; Zhang Y; Xiao Zj


Chinese Journal of Hematology | 2009

Study on karyotypic abnormalities and its prognostic significance in Chinese patients with primary myelodysplastic syndromes

Li L; Liu Xp; Nie L; Yu Mh; Zhang Y; Qin Tj; Xiao Zj


Chinese Journal of Hematology | 2013

Detection and analysis of factor VIII exon 14 mutation in severe hemophilia A patients

Zhang Al; Yang L; Liu Xe; Zhang Y; Qi Xl


Chinese Journal of Hematology | 2012

Study on the role of fluorescence in situ hybridization in cytogenetic evaluation of myelodysplastic syndrome

Shi qiang Qu; Ze feng Xu; Cheng wen Li; Xu ping Liu; Tie jun Qin; Zhang Y; Zhi jian Xiao


Chinese Journal of Hematology | 2011

Study on prognostic significances of different cytogenetic risk categories in patients with primary myelodysplastic syndromes

Qu S; Liu Xp; Xu Zf; Zhang Y; Qin Tj; Zhang Tj; Cui R; Hao Ys; Xiao Zj


Chinese Journal of Hematology | 2009

[Re-evaluation of classification of myelodysplastic syndromes with low percentage bone marrow blasts].

Yu Mh; Xu Zf; Li L; Nie L; Liu L; Zhang Y; Qin Tj; Hao Ys; Xiao Zj


Chinese Journal of Hematology | 2009

The efficacy of imatinib mesylate for patients with myeloproliferative neoplasm (MPN) with eosinophilia

Zhang Y; Qin Tj; Zhou Cl; Liu L; Xiao Zj

Collaboration


Dive into the Zhang Y's collaboration.

Top Co-Authors

Avatar

Chengwen Li

Peking Union Medical College

View shared research outputs
Top Co-Authors

Avatar

Peihong Zhang

Peking Union Medical College

View shared research outputs
Researchain Logo
Decentralizing Knowledge